Drug Discov Ther. 2017;11(3):152-155. (DOI: 10.5582/ddt.2017.01022)

Intratumor dihydropyrimidine dehydrogenase mRNA expression levels are decreased in extramammary Paget's disease.

Nakamura Y, Kajihara I, Yamada-Kanazawa S, Maeda-Otsuka S, Johno T, Aoi J, Igata T, Masuguchi S, Fukushima S, Jinnin M, Ihn H


S-1, a 5-fluorouracil (5-FU)-based anti-cancer agent, is an important drug for treating metastatic extramammary Paget's disease (EMPD). Although intratumor expression levels of 5-FU metabolism enzymes have been studied widely in many solid tumors, no studies have examined on the expression levels of thymidylate synthase (TS), orotate phosphoribosyl-transferase (OPRT) or dihydropyrimidine dehydrogenase (DPD) in skin cancers. The aim of this study was to estimate the intratumoral mRNA expression levels of these genes in EMPD by real time PCR. Intratumoral DPD mRNA levels were decreased in EMPD compared to those in normal skin, but its intratumoral DPD mRNA expression levels were not correlated with clinical manifestations. Intratumoral DPD mRNA levels were positively correlated with OPRT mRNA levels in EMPD. Based on these results, low expression of intratumoral DPD mRNA in EMPD may contribute to the pathogenesis of this disease.

KEYWORDS: S-1, extramammary Paget's disease, mRNA, real time PCR, thymidylate synthase, orotate phosphoribosyl-transferase, dihydropyrimidine dehydrogenase

Full Text: